

# Know Labs, Inc. Reports Second Quarter FY 2024 Results

SEATTLE--(BUSINESS WIRE)-- [Know Labs, Inc.](#) (NYSE American: KNW), a leading developer of non-invasive medical diagnostic technology, today reported financial results for the second quarter of the fiscal year 2024 ended March 31, 2024.

## Financial Highlights:

- In Q2 FY 2024, Know Labs reported an operating loss of \$4.73 million dollars, compared to an operating loss of \$4.81 million dollars in Q2 FY 2023, a reduction in operating loss of 1.7%. This translates to Earnings Per Share of a loss of \$0.07, better than the prior year quarter Earnings Per Share Loss of \$0.10, an improvement of 30%, before preferred stock dividends.
- Recorded a non-cash charge to earnings of \$976,000 principally related to stock-based compensation of \$617,000 and issuance of common stock for services of \$251,000.
- Research and development expense for Q2 FY 2024 was \$2.18 million dollars as compared to \$2.56 million dollars in Q2 FY 2023, a decrease of 15.1% year over year. The decrease in R&D expense was related to decreased personnel and the use of external consultants to reduce the cost of product development.
- Selling, general and administrative expenses for Q2 FY 2024 was \$2.55 million, which was higher by \$308,000 than the \$2.24 million dollars in the year ago period, an increase of 13.7%, reflecting key hires made in the quarter, as well as an increase in legal expenses related to IP and financing activities.
- As of March 31, 2024, Know Labs had cash and cash equivalents of \$4.71 million dollars, as compared to \$8.02 million at the end of September 30, 2023. Net cash used in operations for the first six months of FY 2024 was \$7.05 million dollars compared with \$6.34 million in the six-month period of FY 2023.
- During the year ended September 30, 2023, the Company made adjustments to its fixed expenses and the impact of those adjustments has significantly reduced the monthly burn rate. Given the significant reduction in fixed expenses, the Company believes that it has enough available cash and flexibility with its operating expenses to operate until at least October 31, 2024. As stated in its Q1 FY 2024 10-Q, the Company expects to raise additional funds through the issuance of equity, preferred stock, and convertible debentures. To that end, on March 20, 2024, the Company entered into an At the Market Offering Agreement with The Benchmark Company, LLC pursuant to which the Company may, from time to time, offer and sell shares of its common stock through or to The Benchmark Company, LLC as its sales agent or manager in an aggregate amount of up to \$5,000,000. In addition, the Company has an \$18 million S-3 shelf registration statement which was subsequently declared effective on January 11, 2024 to facilitate liquidity needs.
- Shareholder equity for Q2 FY 2024 was a negative \$1.75 million versus \$3.74 million in FY 2023, ending September 30, 2023. The Company is actively taking steps to address its negative shareholder equity through the conversion of convertible debt to equity, as well as new equity issuance as previously mentioned.

As previously disclosed in its annual report on Form 10-K for the fiscal year ended September 30, 2023, which was filed with the Securities and Exchange Commission on December 19, 2023, the audit opinion contained a going concern qualification from the Company's independent registered public accounting firm. This announcement is being made solely to comply with the New York Stock Exchange's Company Guide Sections 401(h) and 610(b), which require separate disclosure of receipt of an audit opinion that contains a going concern qualification. This announcement does not represent any change or amendment to the Company's 2023 audited financial statements or to its 2023 annual report on Form 10-K.

**Conference Call:**

Know Labs will host an audio webcast to discuss its results and provide a business update today, May 15, 2024, at 4:30 pm ET (1:30 pm PT). The live webcast will be available on the Investors page of the Company's website, <https://ir.knowlabs.co/>, and a replay will be available for six months.

Participant Dial-In: 877-514-3621 / +1 215-268-9856

Webcast: <https://event.choruscall.com/mediaframe/webcast.html?webcastid=SyKIAQ9X>

A copy of the form 10-Q filed with the SEC can also be downloaded from the Company's website.

**Income Statement:**

	Three Months Ended,		Six Months Ended,	
	March 31, 2024	March 31, 2023	March 31, 2024	March 31, 2023
	Unaudited	Unaudited	Unaudited	Unaudited
<b>OPERATING EXPENSES-</b>				
RESEARCH AND DEVELOPMENT EXPENSES	\$ 2,175,245	\$ 2,563,469	\$ 3,661,633	\$ 4,306,520
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES	2,550,848	2,242,658	4,538,657	4,147,729
Total operating expenses	4,726,093	4,806,127	8,200,290	8,454,249
OPERATING LOSS	(4,726,093)	(4,806,127)	(8,200,290)	(8,454,249)
<b>OTHER INCOME (EXPENSE), NET</b>				
Interest income	45,243	-	96,253	-
Interest expense	(716,814)	(124,075)	(740,251)	(298,812)
Total other expense, net	(671,571)	(124,075)	(643,998)	(298,812)
LOSS BEFORE INCOME TAXES	(5,397,664)	(4,930,202)	(8,844,288)	(8,753,061)
Income tax expense	-	-	-	-
NET LOSS	(5,397,664)	(4,930,202)	(8,844,288)	(8,753,061)
Deemed dividends on Series C and D Preferred Stock	(98,609)	-	(162,238)	-
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS	\$ (5,496,273)	\$ (4,930,202)	\$ (9,006,526)	\$ (8,753,061)
Basic and diluted loss per share	\$ (0.07)	\$ (0.10)	\$ (0.11)	\$ (0.18)
Weighted average shares of common stock outstanding- basic and diluted	81,766,128	48,207,937	81,428,231	48,197,581

## **Balance Sheet:**

	March 31, 2024	September 30, 2023
	Unaudited	(1)
<b>ASSETS</b>		
CURRENT ASSETS:		
Cash and cash equivalents	\$ 4,709,690	\$ 8,023,716
Total current assets	<u>4,709,690</u>	<u>8,023,716</u>
PROPERTY AND EQUIPMENT, NET	55,655	81,325
OTHER ASSETS		
Other assets	163,628	15,766
Operating lease right-of-use asset	9,175	145,090
	<u>4,938,148</u>	<u>8,265,897</u>
<b>LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY</b>		
CURRENT LIABILITIES:		
Accounts payable - trade	\$ 1,031,600	\$ 1,292,861
Accrued expenses	98,954	94,062
Accrued expenses - related parties	97,822	218,334
Current portion of convertible notes payable, net	3,819,660	2,761,931
Current portion of operating lease right-of-use liability	14,500	154,797
Total current liabilities	<u>5,062,536</u>	<u>4,521,985</u>
NON-CURRENT LIABILITIES:		
Non-current portion of convertible notes payable, net	1,629,586	-
Total liabilities	<u>6,692,122</u>	<u>4,521,985</u>
COMMITMENTS AND CONTINGENCIES (Note 11)		
STOCKHOLDERS' (DEFICIT) EQUITY		
Preferred stock - \$0.001 par value, 5,000,000 shares authorized, Series C and D shares		
issued and outstanding as follows:		
Series C Convertible Preferred stock \$0.001 par value, 30,000 shares authorized, 17,858 shares issued and outstanding at 3/31/2024 and 9/30/2023, respectively	1,790	1,790
Series D Convertible Preferred stock \$0.001 par value, 20,000 shares authorized, 10,161 shares issued and outstanding at 3/31/2024 and 9/30/2023, respectively	1,015	1,015
Common stock - \$0.001 par value, 200,000,000 shares authorized, 82,512,166 and 80,358,463 shares issued and outstanding at 3/31/2024 and 9/30/2023, respectively	82,512	80,358
Additional paid in capital	129,008,023	125,501,537
Accumulated deficit	(130,847,314)	(121,840,788)
Total stockholders' (deficit) equity	<u>(1,753,974)</u>	<u>3,743,912</u>
TOTAL LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY	<u>\$ 4,938,148</u>	<u>\$ 8,265,897</u>

## **Cash Flow:**

	Six Months Ended,	
	March 31, 2024	March 31, 2023
	Unaudited	Unaudited
<b>CASH FLOWS FROM OPERATING ACTIVITIES:</b>		
Net loss	\$ (8,844,288)	\$ (8,753,061)
Adjustments to reconcile net loss to net cash (used in) operating activities		
Depreciation and amortization	38,367	205,094
Stock based compensation - stock option grants	1,315,563	1,927,187
Issuance of common stock for services	277,010	-
Amortization of operating lease right-of-use asset	135,915	89,612
Amortization of debt issuance costs	100,029	-
Interest expense for extension of notes and warrants	594,761	349,721
Changes in operating assets and liabilities:		
Other long-term assets	(147,862)	(1,999)
Operating lease right-of-use liability	(140,297)	(92,270)
Accounts payable - trade and accrued expenses	(376,882)	(64,933)
<b>NET CASH (USED IN) OPERATING ACTIVITIES</b>	<b>(7,047,684)</b>	<b>(6,340,649)</b>
<b>CASH FLOWS FROM INVESTING ACTIVITIES:</b>		
Purchase of research and development equipment	(12,696)	(41,857)
<b>NET CASH (USED IN) INVESTING ACTIVITIES:</b>	<b>(12,696)</b>	<b>(41,857)</b>
<b>CASH FLOWS FROM FINANCING ACTIVITIES:</b>		
Proceeds from debt offering	3,805,699	-
Proceeds from issuance of common stock offering, net	203,105	-
Payments for debt offering	(262,450)	-
Proceeds from issuance of common stock for stock options exercise	-	2,343
Proceeds from issuance of common stock for warrant exercise	-	12,500
<b>NET CASH PROVIDED BY FINANCING ACTIVITIES</b>	<b>3,746,354</b>	<b>14,843</b>
<b>NET (DECREASE) IN CASH AND CASH EQUIVALENTS</b>	<b>(3,314,026)</b>	<b>(6,367,663)</b>
CASH AND CASH EQUIVALENTS, beginning of period	8,023,716	12,593,692
CASH AND CASH EQUIVALENTS, end of period	\$ <u>4,709,690</u>	\$ <u>6,226,029</u>
Supplemental disclosure of non-cash financing activity:		
Deemed dividends on Series C and D Preferred Stock	\$ 162,238	\$ -
Warrants issued for debt offering	\$ 1,536,743	\$ -

## About Know Labs, Inc.

[Know Labs, Inc.](#) is a public company whose shares trade on the NYSE American Exchange under the stock symbol "KNW." The Company's platform technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The technology can be integrated into a variety of wearable, mobile or bench-top form factors. This patented and patent-pending technology makes it possible to effectively identify and monitor analytes that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. The first application of the technology will be in a product marketed as a non-invasive glucose monitor. The device will provide the user with accessible and affordable real-time information on blood glucose levels. This product will require U.S. Food and Drug Administration clearance prior to its introduction to the market.

## **Safe Harbor Statement**

This release contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Know Labs, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy; and (iv) performance of products. You can identify these statements by the use of the words “may,” “will,” “could,” “should,” “would,” “plans,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” “likely,” “forecast,” “probable,” “potential,” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Know Labs, Inc.’s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. These risks and uncertainties also include such additional risk factors as are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended September 30, 2023, Forms 10-Q and 8-K, and in other filings we make with the Securities and Exchange Commission from time to time. These documents are available on the SEC Filings section of the Investor Relations section of our website at [www.knowlabs.co](http://www.knowlabs.co). The Company cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. The Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made.

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20240515814526/en/>

### **For Know Labs Media Inquiries Contact:**

Matter Health

Abby Mayo

[Knowlabs@matternow.com](mailto:Knowlabs@matternow.com)

Ph. (617) 272-0592

### **Know Labs, Inc. Contact:**

Jordyn Hujar

[jordyn@knowlabs.co](mailto:jordyn@knowlabs.co)

Ph. (206) 629-6414

Source: Know Labs, Inc.